Quidel acquires InflammaDry and AdenoPlus

iStock-182146447.jpg

Quidel (NASDAQ:QDEL) has acquired the InflammaDry and AdenoPlus diagnostic businesses from RPS Diagnostics for about $14-million. 

InflammaDry is the only point-of-care test that detects elevated levels of MMP-9, a key inflammatory marker for dry eye. AdenoPlus is a test that differentiates between a viral and bacterial infection of acute conjunctivitis, or pink eye.

Both products utilize innovative patented technology, are CE marked, FDA-cleared, CLIA-waived, and complement Quidel's existing rapid diagnostic testing solutions. Manufacturing for both products will be transferred to Quidel's San Diego facility in the near term.

"InflammaDry and AdenoPlus products represent a solid growth opportunity in adjacent markets for Quidel," Douglas Bryant, president and CEO of Quidel, said in a statement. "The addition of these two product lines will further strengthen our position in CLIA-waived diagnostic testing at the point-of-care."